Liraglutide, a GLP-1 analog, significantly reduced cardiac hypertrophy and fibrosis and improved cardiac function in a non-diabetic animal model of cardiac hypertrophy induced by Ang II or pressure overload by modulation of PI3K/Akt1 and AMPKα signaling [161]. The gene discussed is AGT; the disease is cardiac hypertrophy.